Latest Helicobacter pylori eradication protocols Stories

THE WOODLANDS, Texas, July 10, 2012 /PRNewswire/ -- Pernix Therapeutics (NYSE: MKT: PTX), a specialty pharmaceutical company, today announced that Omeclamox-Pak(®) is now available to patients for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease (active or one-year history) to eradicate H. pylori in adult patients. Omeclamox-Pak is a ten-day, triple combination oral therapy comprised of omeprazole delayed-release capsules (20 mg),...

Helicobacter pylori (H. pylori) is the causal agent of chronic gastritis, ulcer and gastric cancer. It has the potential to persist in the human stomach for decades, sometimes causing neither harm nor clinical symptoms. Nevertheless, on some occasions, depending on the host immune system and the strain causing the infection, the outcome can be very serious. To maintain the infection, the bacterium must adapt to survive the host defences. One way to accomplish this is to sequentially change...

Although it has been demonstrated that Helicobacter pylori causes gastric cancer, it is still controversial that whether H. pylori eradication therapy is effective in primary prevention of gastric cancer. This is especially important for Yamagata Prefecture, a region of Japan with the second highest incidence of gastric cancer in the world.A research article to be published on September 14, 2009 in the World Journal of Gastroenterology addresses this question. A research team led by Dr....

Bismuth compounds have been used for centuries in medicine. The discovery of H. pylori in 1983 led to renewed interest in bismuth compounds, because these were found to successfully treat the infection in combination with antibiotics. However, in the 1970s bismuth salts, used at high doses for prolonged periods, were found to lead to neurotoxicity. There has been no summary of evidence for the toxicity of bismuth when used for short periods as part of H. pylori eradication therapy.A research...